Další formáty:
BibTeX
LaTeX
RIS
@article{970396,
author = {Václavík, Jan and Sedlak, Richard and Plachy, Martin and Navratil, Karel and Plasek, Jiří and Jarkovský, Jiří and Vaclavik, Tomáš and Husar, Roman and Kocianova, Eva and Taborsky, Miloš},
article_number = {6},
doi = {http://dx.doi.org/10.1161/HYPERTENSIONAHA.111.169961},
keywords = {resistant hypertension; spironolactone; clinical trials; blood pressure; ambulatory blood pressure monitoring},
language = {eng},
issn = {0194-911X},
journal = {HYPERTENSION},
title = {Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial},
volume = {57},
year = {2011}
}
TY - JOUR
ID - 970396
AU - Václavík, Jan - Sedlak, Richard - Plachy, Martin - Navratil, Karel - Plasek, Jiří - Jarkovský, Jiří - Vaclavik, Tomáš - Husar, Roman - Kocianova, Eva - Taborsky, Miloš
PY - 2011
TI - Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial
JF - HYPERTENSION
VL - 57
IS - 6
SP - 1069-1075
EP - 1069-1075
SN - 0194911X
KW - resistant hypertension
KW - spironolactone
KW - clinical trials
KW - blood pressure
KW - ambulatory blood pressure monitoring
N2 - There is currently limited data on which drug should be used to improve blood pressure (BP) control in patients with resistant hypertension. This study was designed to assess the effect of the addition of 25 mg of spironolactone on BP in patients with resistant arterial hypertension. Patients with office systolic BP >140 mm Hg or diastolic BP >90 mm Hg despite treatment with at least 3 antihypertensive drugs, including a diuretic, were enrolled in this double-blind, placebo-controlled, multicenter trial. One hundred seventeen patients were randomly assigned to receive spironolactone (n=59) or a placebo (n=58) as an add-on to their antihypertensive medication, by the method of simple randomization. Analyses were done with 111 patients (55 in the spironolactone and 56 in the placebo groups). At 8 weeks, the primary end points, a difference in mean fall of BP on daytime ambulatory BP monitoring (ABPM), between the groups was -5.4 mm Hg (95%CI -10.0; -0.8) for systolic BP (P=0.024) and -1.0 mm Hg (95% CI -4.0; 2.0) for diastolic BP (P=0.358). The APBM nighttime systolic, 24-hour ABPM systolic, and office systolic BP values were significantly decreased by spironolactone (difference of -8.6, -9.8, and -6.5 mm Hg; P=0.011, 0.004, and 0.011), whereas the fall of the respective diastolic BP values was not significant (-3.0, -1.0, and -2.5 mm Hg; P=0.079, 0.405, and 0.079). The adverse events in both groups were comparable. In conclusion, spironolactone is an effective drug for lowering systolic BP in patients with resistant arterial hypertension.
ER -
VÁCLAVÍK, Jan, Richard SEDLAK, Martin PLACHY, Karel NAVRATIL, Jiří PLASEK, Jiří JARKOVSKÝ, Tomáš VACLAVIK, Roman HUSAR, Eva KOCIANOVA a Miloš TABORSKY. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial. \textit{HYPERTENSION}. 2011, roč.~57, č.~6, s.~1069-1075. ISSN~0194-911X. Dostupné z: https://dx.doi.org/10.1161/HYPERTENSIONAHA.111.169961.
|
